NCT02341807View on ClinicalTrials.gov

Safety and Dose-escalation Study of AAV2-hCHM in Participants With CHM (Choroideremia) Gene Mutations

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 15, 2015

Primary Completion Date

October 12, 2022

Study Completion Date

October 12, 2022

Conditions
ChoroideremiaCHM (Choroideremia) Gene Mutations
Interventions
BIOLOGICAL

AAV2-hCHM

Comparison of different dosages of AAV2-hCHM

Trial Locations (3)

19014

University of Pennsylvania, Philadelphia

19104

Children's Hospital of Philadelphia, Philadelphia

02114

Massachusetts Eye and Ear Infirmary, Boston

All Listed Sponsors
lead

Spark Therapeutics, Inc.

INDUSTRY

NCT02341807 - Safety and Dose-escalation Study of AAV2-hCHM in Participants With CHM (Choroideremia) Gene Mutations | Biotech Hunter | Biotech Hunter